Literature DB >> 12643374

Small cell carcinoma of the esophagus: the Tata Memorial Hospital experience.

Gouri H Pantvaidya1, C S Pramesh, Mandar S Deshpande, Nirmala A Jambhekar, Sanjay Sharma, Ramakant K Deshpande.   

Abstract

BACKGROUND: Small cell carcinoma of the esophagus is a rare disease, characterized by aggressive progression. It has a high incidence of metastatic disease at presentation and a poor overall prognosis. Treatment protocols are not well established because of the paucity of cases and a lack of large studies.
METHODS: We performed a retrospective review of all patients with small cell carcinoma of the esophagus diagnosed at the Tata Memorial Hospital between 1985 and 2001. We retrieved and analyzed data regarding demographic details, diagnosis, staging, type of treatment, and overall survival.
RESULTS: Eighteen patients with a mean age of 62 years (range 48 to 80 years) diagnosed as having small cell carcinoma of the esophagus were analyzed. The group included 13 men and 5 women. Seven of the 18 patients (39%) presented with metastatic disease including 5 patients (28%) with liver metastases. Four patients were treated with surgery, with or without chemotherapy or radiotherapy. Three patients were treated with combination chemoradiotherapy, 2 patients with chemotherapy alone, and 5 patients with radiotherapy alone. Four patients with advanced disease and poor general condition were not offered any treatment. The overall median survival of our patients was 6 months. Patients treated with surgery and chemotherapy had a better overall survival.
CONCLUSIONS: Small cell carcinoma of the esophagus should be regarded as a systemic disease with a high distant failure rate. Treatment strategies hence must incorporate systemic chemotherapy along with radical surgery or radiotherapy as part of a multimodality approach.

Entities:  

Mesh:

Year:  2002        PMID: 12643374     DOI: 10.1016/s0003-4975(02)04061-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  17 in total

1.  SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesis.

Authors:  Hirotaka Ishida; Atsuko Kasajima; Takashi Kamei; Tsuyoshi Miura; Naomi Oka; Samaneh Yazdani; Yohei Ozawa; Fumiyoshi Fujishima; Akira Sakurada; Yasuhiro Nakamura; Yoichi Tanaka; Masafumi Kurosumi; Yuichi Ishikawa; Yoshinori Okada; Noriaki Ohuchi; Hironobu Sasano
Journal:  Mod Pathol       Date:  2017-01-20       Impact factor: 7.842

2.  A retrospective study of definitive chemoradiotherapy in patients with resectable small cell neuroendocrine carcinoma of the esophagus.

Authors:  Chikatoshi Katada; Shouko Komori; Tsutomu Yoshida; Shogo Kawakami; Akinori Watanabe; Kenji Ishido; Mizutomo Azuma; Takuya Wada; Kei Hosoda; Keishi Yamashita; Naoki Hiki; Satoshi Tanabe; Hiromichi Ishiyama; Wasaburo Koizumi
Journal:  Esophagus       Date:  2019-07-18       Impact factor: 4.230

Review 3.  Primary small cell carcinoma of esophagus: report of 9 cases and review of literature.

Authors:  Zhu Wu; Jian-Yang Ma; Jun-Jie Yang; Yong-Fan Zhao; Shang-Fu Zhang
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

4.  Primary Small Cell Carcinoma of The Esophagus - An Eight Year Retrospective Study.

Authors:  Bhavna Nayal; Geetha Vasudevan; Anuradha C K Rao; Ranjini Kudva; Manna Valliathan; Mary Mathew; Lakshmi Rao
Journal:  J Clin Diagn Res       Date:  2015-05-01

5.  Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients.

Authors:  Yigong Zhang; Cong Li; Ming Chen
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

6.  Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature.

Authors:  Haridimos Markogiannakis; Dimitrios Theodorou; Konstantinos G Toutouzas; Andreas Larentzakis; Michael Pattas; Angeliki Bousiotou; Pavlos Papacostas; Konstantinos Filis; Stilianos Katsaragakis
Journal:  J Med Case Rep       Date:  2008-01-22

7.  Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma.

Authors:  Huan-Huan Wang; Nicholas G Zaorsky; Mao-Bin Meng; Zhi-Qiang Wu; Xian-Liang Zeng; Bo Jiang; Chao Jiang; Lu-Jun Zhao; Zhi-Yong Yuan; Ping Wang
Journal:  Onco Targets Ther       Date:  2015-02-13       Impact factor: 4.147

Review 8.  Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.

Authors:  Emma Elizabeth Ilett; Seppo W Langer; Ingrid Holst Olsen; Birgitte Federspiel; Andreas Kjær; Ulrich Knigge
Journal:  Diagnostics (Basel)       Date:  2015-04-08

9.  Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: An Update.

Authors:  Stefano La Rosa; Alessandro Marando; Fausto Sessa; Carlo Capella
Journal:  Cancers (Basel)       Date:  2012-01-16       Impact factor: 6.639

10.  Primary Small Cell Carcinoma of the Esophagus: Clinico- pathological Features and Therapeutic Options.

Authors:  Andrea Nevárez; A Saftoiu; M S Bhutani
Journal:  Curr Health Sci J       Date:  2011-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.